What Sildenafil EG Treats: Main Uses and Benefits

Sildenafil is considered relevant for managing two distinct categories of conditions: impaired erectile function in adult males and certain forms of Pulmonary Arterial Hypertension (PAH). It is applied across domains where additional symptomatic support is needed to address symptoms that create noticeable physiological strain.

---

Supporting Functional Stability for Sexual Performance

Sildenafil EG is commonly used to help with vascular-dependent functional impairment in adult males, specifically used for managing the inability to achieve or sustain a satisfactory erection. The medication is relevant when symptoms interfere with daily comfort, and supports functional stability relevant to sexual performance.

---

Supportive Management of Pulmonary Arterial Hypertension

It is used across conditions characterized by chronic, fluctuating manifestations, such as PAH, which is associated with symptoms like shortness of breath and tiredness limiting physical capacity. It provides support that helps ease the overall symptom burden by providing supportive relief for symptoms associated with high pressure in the lungs, and may assist with improving exercise capacity. This contributes to improved day-to-day comfort for patients, including pediatric groups aged 1 and older.

---

Therapeutic Focus

Focus Area	Symptom Domain Managed
Functional Strain	Impaired Erectile Function in adult men
Symptom Burden	Shortness of Breath and Tiredness associated with PAH

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Profile: Official Regulatory Information

The eligibility for Sildenafil EG is defined by official regulatory documentation, which sets clear constraints on patient populations and co-medications.

Contraindicated Populations (Must Not Use)

• Nitrate Use: Individuals concurrently receiving any form of organic nitrate or the guanylate cyclase stimulator riociguat are absolutely prohibited from using Sildenafil EG.
• Severe Comorbidities: Use is prohibited for patients with a recent history of myocardial infarction or stroke, severe hypotension (blood pressure < 90/50 mmHg), or severe hepatic impairment (Child-Pugh class C).
• Cardiovascular Risk: The medicine is contraindicated in men for whom sexual activity is inadvisable due to severe cardiovascular disorders.

Age-Group Eligibility

• Adults are the primary approved group. The medicine is not indicated for Erectile Dysfunction in individuals under 18 years of age.
• For Pulmonary Arterial Hypertension (PAH), use is approved for adults and children aged 1 year and older.
• Safety and efficacy have not been established in infants less than 1 year of age.

Conditional Use

Use requires caution or special consideration for patients with severe renal impairment (creatinine clearance < 30 mL/min) and those with conditions predisposing to priapism (e.g., sickle cell anaemia).

Interactions with other medicines and products

Contraindicated Combinations

Sildenafil is contraindicated for use with certain medications due to the risk of severe, life-threatening hypotension (dangerously low blood pressure). These include:

• Any form of nitrates or nitric oxide donors (e.g., nitroglycerin, isosorbide dinitrate), as sildenafil significantly enhances their blood pressure-lowering effects.
• Guanylate cyclase (GC) stimulators, such as riociguat, which also act on the nitric oxide pathway and may cause a critical drop in blood pressure when combined with sildenafil.

Combinations Requiring Caution or Dose Adjustment

Sildenafil's metabolism is primarily carried out by the liver enzyme CYP3A4. Medications that inhibit this enzyme can increase sildenafil concentrations in the body, raising the risk of side effects.

• Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, erythromycin) may require a reduced starting dose of sildenafil (e.g., 25 mg). Co-administration with ritonavir, specifically, mandates a maximum sildenafil dose of 25 mg within a 48-hour period.
• Alpha-blockers and other anti-hypertensive medicines can increase the risk of symptomatic low blood pressure. Patients should be hemodynamically stable on alpha-blocker therapy before initiating sildenafil, and a 25 mg starting dose of sildenafil should be considered.
• Co-administration with other treatments for erectile dysfunction, including other PDE5 inhibitors (e.g., tadalafil), is not recommended as their combined effects have not been adequately studied.

How Sildenafil EG Works

Selective Inhibition of the PDE5 Enzyme

Sildenafil EG operates by acting as a selective competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). PDE5 is the primary molecular target responsible for the rapid degradation of cyclic Guanosine Monophosphate (cGMP) within smooth muscle cells. The drug's mechanistic domain is focused on enzyme inhibition to prevent the breakdown of this secondary messenger.

---

Amplification of the Nitric Oxide (NO) Signal

This mechanism functions by modulating the Nitric Oxide (NO)/ cGMP pathway. NO is a natural mediator that triggers the production of cGMP, which leads to muscle relaxation. By blocking PDE5, Sildenafil amplifies this signal, resulting in elevated and sustained cGMP levels that cascade into vascular smooth muscle relaxation and subsequently localized vasodilation.

---

Physiological Result: Increase in Local Blood Flow

The end consequence of this mechanism is a direct physiological adjustment: the widening of the blood vessels. This sustained vasodilation in specific vascular beds results in an increase in local blood flow, provided the NO signal has been initiated by the body. This NO-dependent requirement represents a key constraint on the physiological consequence of the mechanism.

The official administration guidelines for Sildenafil EG, which contains the active ingredient sildenafil, depend on the specific condition being treated (Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH)).

Oral Use for Erectile Dysfunction (ED)

Guideline	Instruction
Route & Form	Oral film-coated tablets (25 mg, 50 mg, 100 mg)
Standard Dosing	Recommended starting dose is 50 mg, taken as needed. The dose may be adjusted between 25 mg and 100 mg based on effectiveness and tolerability.
Timing & Frequency	Take approximately one hour before sexual activity, but may be taken from 30 minutes to 4 hours prior. Do not take more than once per day.
Food Condition	May be taken with or without food. However, taking it with a high-fat meal may delay the onset of action.
Special Populations	A lower starting dose of 25 mg should be considered for patients 65 years old, those with severe renal impairment (creatinine clearance <30 mL/min), or those with hepatic impairment (e.g., cirrhosis).

Use for Pulmonary Arterial Hypertension (PAH)

Sildenafil is also available as a 20 mg tablet, oral suspension, and intravenous injection for PAH treatment. The standard adult oral dose is 20 mg three times a day (TID), taken approximately 4 to 6 hours apart. Pediatric dosing is based on body weight, with children receiving 10 mg or 20 mg TID depending on weight. Intravenous administration is typically 10 mg as a bolus injection TID, used when patients are temporarily unable to take oral medication.

Research Evidence / Overview of Studies for Sildenafil EG

Evidence for Use in Erectile Dysfunction (ED)

The research base includes studies evaluating functional impairment in adult men, known as Erectile Dysfunction (ED). The evidence is derived from multiple short-term (12–24 week) randomized, placebo-controlled clinical trials (RCTs). These studies compare reported outcomes to an inactive substance. Research for ED was studied for changes related to patient-reported experiences of daily-life functioning, using specific tools such as the International Index of Erectile Function (IIEF). Studies monitored changes in these scores and reported patterns related to patient experience when compared to those receiving placebo.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Studies evaluating Pulmonary Arterial Hypertension (PAH) were conducted using controlled trials focusing on conditions marked by functional limitations and physiological strain. The core research involved short-term (12–16 week) RCTs that monitored how participants' activity level changed. A key measurement used in these studies was the 6-minute walk distance (6MWD) test, which is a standardized way of measuring outcomes related to physical discomfort. Research also examined changes in hemodynamic biomarkers, such as the pulmonary arterial pressure. Findings indicate patterns of change measured during the study period in both the 6MWD and these pressure readings when compared to placebo groups.

---

Long-Term Studies and Observation Periods

Research explored the long-term course of Sildenafil EG's use through studies conducted over defined time intervals. The initial pivotal RCTs were short-term. The evidence contributes to understanding short-term changes, but there is limited information regarding sustained functional outcomes over the long term in controlled settings. To gain insight into sustained use, researchers conducted long-term open-label extension studies, which are observational and do not offer the same level of certainty as a controlled trial.

---

What Remains Uncertain and Research Gaps

One key limitation is the lack of comprehensive, controlled, multi-year data for both indications, as follow-up durations were limited in the initial primary efficacy trials. For the use in pediatric PAH, evidence quality varies across studies, and findings varied across studies regarding outcomes in children. Research is ongoing, but there is limited information for long-term outcomes related to all-cause mortality, particularly in this younger population, and the certainty remains low. This evidence provides context regarding what is known—and what is still uncertain—about long-term use.

Common questions about Sildenafil EG (FAQ)

Q: Is Sildenafil EG a prescription-only medicine?

According to official regulatory classifications, Sildenafil for its approved medical uses, such as Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH), is primarily classified as a prescription-only medicine in most countries. This means a valid prescription from a licensed healthcare professional is typically required to obtain the medicine.

Q: How long does Sildenafil EG take to start working?

Regulatory documents indicate that the medicine is absorbed relatively quickly after taking it by mouth. The maximum concentration in the blood is typically reached within 30 to 120 minutes (median one hour) when the medicine is taken without food.

Q: How long does the effect of Sildenafil EG last?

Studies on the drug's properties indicate that the plasma half-life of Sildenafil is approximately 3 to 5 hours. The drug's action requires the body's natural signaling to be initiated, such as during sexual stimulation.

Q: Is there any long-term safety data for Sildenafil EG?

Official information indicates that controlled clinical trials for efficacy were typically short-term (e.g., up to 24 weeks). Information on sustained outcomes and long-term safety is often drawn from open-label extension studies, which are observational and generally do not provide the same level of certainty as initial controlled trials.

Q: How should I act if I miss a dose of Sildenafil EG for PAH?

Official labeling for Pulmonary Arterial Hypertension ( PAH) provides guidance on missed doses. It generally advises taking the dose when remembered, unless the time is close to the next scheduled administration. The guidance also states that doses should not be doubled to compensate for a missed dose.

Q: What should I do if I take too much Sildenafil EG (overdose)?

Regulatory documents indicate that in the event of an overdose, standard supportive measures should be adopted as required. High doses have been associated with increased frequency and severity of adverse reactions. Official information also notes that Sildenafil is highly protein-bound and is not expected to be cleared significantly by renal dialysis.

Q: How do I know if I have the rare condition NAION (sudden vision loss)?

Official warnings regarding the eye advise that if sudden vision loss occurs in one or both eyes, the use of the medicine should be discontinued and immediate medical evaluation sought. This change may be a sign of a rare but serious condition called Non-arteritic Anterior Ischemic Optic Neuropathy ( NAION).

Q: Can women take Sildenafil EG?

Sildenafil EG is not indicated for Erectile Dysfunction in women. However, Sildenafil is an approved treatment for Pulmonary Arterial Hypertension ( PAH) in both sexes. Specific regulatory information is available concerning the use of the medicine during pregnancy or lactation for women being treated for PAH.

Storage and Handling Requirements

Sildenafil EG tablets must be stored strictly according to the conditions defined in the regulatory labeling to protect the product's quality and ensure safety.

Storage Classification	Mandatory Conditions
Temperature	Store at room temperature, typically defined as 20 C to 25 C (68 F to 77 F), and keep away from excess heat [FDA, NIH].
Protection	Store in the original package to protect from moisture [EMA, NIH]. Do not store the medicine in a bathroom or other damp areas [NIH].
Container/Safety	The container must be kept tightly closed and stored out of the sight and reach of children [NIH, MHRA].

---

Official Disposal Rules

Disposal instructions for Sildenafil EG are defined to prevent environmental contamination:

• Do not dispose of via wastewater or household trash [EMA].
• Unused or expired medicine must be returned via established return systems or disposed of according to local requirements [EMA].